Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 16/20 | 0.51 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3699875 | 0.88 | TLR7 (0.51) | TLR7TLR8THRATHRB | |
| Guanidine SCHEMBL854548 | 0.84 | TLR7 (0.50) | TLR7TLR8 | |
| SCHEMBL3705743 | 0.82 | NPSR1 (0.65) | NPSR1TLR7TLR8KDM4E | |
| SCHEMBL3701040 | 0.81 | TLR7 (0.63) | TLR7 | |
| SCHEMBL854549 | 0.81 | TLR7 (0.47) | TLR7TLR8 | |
| SCHEMBL6119291 | 0.78 | TLR7 (0.72) | TLR7TLR8 | |
| SCHEMBL8887148 | 0.78 | TLR7 (0.72) | TLR7TLR8 | |
| Hydrochloric Acid SCHEMBL855557 | 0.78 | NPSR1 (0.60) | NPSR1TLR7TLR8KDM4E | |
| SCHEMBL6118784 | 0.77 | TLR7 (0.80) | TLR7TLR8 | |
| SCHEMBL6118752 | 0.77 | TLR7 (0.80) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432768-B1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-9533978-B2 | Pyrimidine derivatives and their use in the treatment of cancer and further diseases | SUMITOMO DAINIPPON PHARMA CO., LTD (JP) | 2017-01-03 | — | — | US | disclosed |
| US-20150080396-A1 | Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2015-03-19 | — | — | US | disclosed |
| CN-102482233-A | Novel pyrimidine derivatives and their use in the treatment of cancer and other diseases | ASTRAZENECA AB SE | 2012-05-30 | — | — | CN | disclosed |
| US-20120122867-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | ASTRAZENECA UK LIMITED (GB) | 2012-05-17 | — | — | US | disclosed |
| EP-2432768-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | AstraZeneca AB (SE) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133885-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122867-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | TYMS, TYMP, DPYD | NPSR1 2520/4885TLR7 2123/4885TLR8 4294/4885 |
| US-20150080396-A1 | Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases | TYMS, TYMP, DPYD | NPSR1 2520/4885TLR7 2123/4885TLR8 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.